Moderna banks $3.3B in latest COVID-19 vaccine supply deal with US, rounding out government’s earmarked doses

The U.S. has been one of Moderna’s most lucrative COVID-19 vaccine customers as the biotech vies for at least $ 19 billion in pandemic shot sales by year’s end.  Just how lucrative? As part of its latest supply deal announced last week, the U.S. will dish out $ 3.3 billion for 200 million shots from… Read More »